Daily Brief : June 14: Deep Tech Moves From Lab to Market

HEADLINE

Endurance Energy raises $54M to tap deep-ocean volcanoes for baseload power as FDA clears Dexcom's OTC glucose monitor for children and the first U.S. carbon nanotube factory opens in Ohio.

THE BIG PICTURE

Today's three stories share a single axis: getting transformative technology out of prototypes and into production at scale. A SpaceX veteran is moving subsea geothermal from ocean trials to power plants; the FDA is removing the physician gatekeeper from pediatric glucose monitoring; and a French deep-tech company is producing advanced materials on U.S. soil. The connecting thread is deployment, not discovery, capital and regulatory appetite are now flowing toward companies that can move from proof-of-concept to commercial operation.

WHAT HAPPENED

Endurance Energy, founded in 2024 by Andrew Redd, a former SpaceX engineer, has closed a $54 million Series A led by Founders Fund to develop geothermal power plants anchored to underwater volcanoes. Geothermal competitors typically drill thousands of feet into remote rock formations far from load centers; Endurance targets seafloor magma that heats water to 728 degrees Fahrenheit. The company has completed four prototype deployments at depths up to nearly 1,000 feet and estimates 6 terawatts of capacity could be developed in the region within five to ten years. The round included Ascend, Construct Capital, Felicis Ventures, First Round Capital, Point72 Ventures, Riot Ventures, and Voyager Ventures. Redd has grown the team to 25, including 12 former SpaceX employees and an ex-Helion Engineering VP. Why it matters: unlike solar and wind, subsea geothermal delivers firm baseload power around the clock, precisely what AI data centers and heavy industry demand, and Founders Fund's check signals that top-tier venture will now fund infrastructure plays that may not generate revenue for years.

The FDA cleared Dexcom Inc.'s Stelo Glucose Biosensor System for over-the-counter use in children aged 2 and older who do not use insulin, becoming the first OTC continuous glucose monitor indicated for a pediatric population. Stelo uses a wearable sensor and smartphone app, reading glucose every 15 minutes and lasting up to 15 days per sensor. The FDA had previously cleared Stelo for adults 18+ in March 2024. The agency relied on real-world evidence rather than mandating a new pediatric clinical trial, a notable expansion of its pragmatic evidence framework. Why it matters: clearing a prescription-class device for pharmacy-shelf access at age 2 removes the physician gatekeeper from glucose monitoring for millions of at-risk children and validates Dexcom's direct-to-consumer expansion.

NAWAH, a French specialist in vertically aligned carbon nanotube materials, opened its first North American manufacturing facility in Englewood, Ohio, a $10 million, 38,000-square-foot plant that moved from site selection to production-ready status in less than 12 months. Built with JobsOhio, the Dayton Development Coalition, and the University of Dayton Research Institute, the facility is expected to reach full production of 400,000 square meters annually by summer 2026. NAWAH-Stitch Film, polymer rolls infused with vertically aligned carbon nanotubes, targets sports equipment, aviation, and aerospace composites. The technology traces roots to research at France's CEA, MIT, and UDRI. Why it matters: NAWAH is the first to industrialize and commercialize vertically aligned carbon nanotubes at scale on U.S. soil, signaling that advanced-materials manufacturing is repatriating and that Ohio's subsidy landscape is competitive with European incentives.

WATCHING

Watch for Endurance Energy's announcement of its first commercial subsea geothermal power plant site and expected timeline, that will validate whether the $54M round opens the path to gigawatt-scale development or remains a long-duration exploration fund. Also track Dexcom's direct-to-consumer volume following the pediatric OTC clearance; if pharmacy penetration moves faster than traditional sales channels, other prescription-device makers will follow.